Gastric Cancer
1,794
317
409
658
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
154 trials with published results (9%)
Research Maturity
658 completed trials (37% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
6.3%
113 terminated out of 1794 trials
85.3%
-1.2% vs benchmark
11%
200 trials in Phase 3/4
23%
154 of 658 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 658 completed trials
Clinical Trials (1794)
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Prehabilitation in High-risk Oncologic Surgery
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Nutrition Intervention Trials in Linxian Follow-up Study
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers